Celltrion biosimilar among CHMP recommendations

EMA’s CHMP recommended approval of a basket of candidates on Friday, including biologics from Pfizer Inc. (NYSE:PFE) and Celltrion Inc. (KOSDAQ:068270).

CHMP recommended Pfizer’s Lifmior etanercept, a product identical to Enbrel, to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis and pediatric plaque psoriasis. Pfizer has worldwide rights to Enbrel from Amgen Inc. (NASDAQ:AMGN) outside the U.S. and Canada. In January, the EC approved Benepali from Samsung Bioepis Co. Ltd., a biosimilar of Enbrel...